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Abstract
Background: A comprehensive network-based understanding of molecular pathways abnormally altered in glioblastoma
multiforme (GBM) is essential for developing effective therapeutic approaches for this deadly disease.
Methodology/Principal Findings: Applying a next generation sequencing technology, massively parallel signature
sequencing (MPSS), we identified a total of 4535 genes that are differentially expressed between normal brain and GBM
tissue. The expression changes of three up-regulated genes, CHI3L1, CHI3L2, and FOXM1, and two down-regulated genes,
neurogranin and L1CAM, were confirmed by quantitative PCR. Pathway analysis revealed that TGF- b pathway related genes
were significantly up-regulated in GBM tumor samples. An integrative pathway analysis of the TGF b signaling network
identified two alternative TGF2b signaling pathways mediated by SOX4 (sex determining region Y-box 4) and TGFBI
(Transforming growth factor beta induced). Quantitative RT-PCR and immunohistochemistry staining demonstrated that
SOX4 and TGFBI expression is elevated in GBM tissues compared with normal brain tissues at both the RNA and protein
levels. In vitro functional studies confirmed that TGFBI and SOX4 expression is increased by TGF- b stimulation and
decreased by a specific inhibitor of TGF- b receptor 1 kinase.
Conclusions/Significance: Our MPSS database for GBM and normal brain tissues provides a useful resource for the scientific
community. The identification of non-SMAD mediated TGF2b signaling pathways acting through SOX4 and TGFBI (GENE
ID:7045) in GBM indicates that these alternative pathways should be considered, in addition to the canonical SMAD
mediated pathway, in the development of new therapeutic strategies targeting TGF2b signaling in GBM. Finally, the
construction of an extended TGF- b signaling network with overlaid gene expression changes between GBM and normal
brain extends our understanding of the biology of GBM.
Citation: Lin B, Madan A, Yoon J-G, Fang X, Yan X, et al. (2010) Massively Parallel Signature Sequencing and Bioinformatics Analysis Identifies Up-Regulation of
TGFBI and SOX4 in Human Glioblastoma. PLoS ONE 5(4): e10210. doi:10.1371/journal.pone.0010210
Editor: Chris Jones, Institute of Cancer Research, United Kingdom
Received December 28, 2009; Accepted March 29, 2010; Published April 19, 2010
Copyright:  2010 Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: We thank the Swedish Medical Foundation for providing financial support for the studies. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Biaoyang.Lin@swedish.org (BL); Greg.Foltz@swedish.org (GF)
. These authors contributed equally to this work.
Introduction
Glioblastoma multiforme (GBM), the most common type of
primary brain cancer, is currently incurable and uniformly fatal. A
comprehensive understanding of molecular pathways underlying
GBM behavior would enable the development of targeted
therapeutic approaches.
In the past several years, DNA microarrays have been used to
identify differential gene expression among different grades of
brain tumors [1], for tumor classification [2–4], prognosis [5,6],
and screening for epigenetic changes [7,8]. Despite these
advances, current DNA microarray technology has limited
detection sensitivity and dynamic range [9] which limits its ability
to detect changes in gene expression at low levels of expression. As
a large number of genes fall into this class of low abundance
expression [10], this lack of sensitivity potentially compromises
current efforts to gain a complete picture of molecular pathways
underlying GBM. To gain a more comprehensive and system-wide
understanding of molecular pathways in GBM, more sensitive
gene expression profiling technology is needed.
Massively parallel sequencing of expressed sequenced tags (also
named massively parallel signature sequencing, MPSS) is a more
sensitive technology in reliably detecting low expression transcripts
[10–12] and has been shown to complement current DNA
microarray technologies [13]. We have therefore used this
technology to help us gain a more complete picture of the
molecular events and networks perturbed in GBM. We applied
MPSS technology to compare the expression profiling of a pool of
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MPSS technology, we were able to identify differential expression
of low abundance genes. We found activation of two alternative
non-SMAD mediated TGF–b signaling subnetworks that act
through SOX4 (sex determining region Y-box 4) and TGFBI
(transforming growth factor b induced transcript). In vitro studies
confirmed that both SOX4 and TFBI are induced by TGF-b and
inhibited by a specific inhibitor of the TGF- b receptor 1 kinase.
Results
MPSS analysis of normal brain and GBM tissues
We sequenced a total of 1,479,906 and 1,521,666 tags
respectively from a pool of five normal brain tissues and a pool
of five GBM tissues. We identified 22,640 MPSS tags that have
significantly expressed tags (.3 tpm in at least one pool),
representing the combined transcriptome of the normal and
GBM tumor tissues (Table S1). 96% of the tags could be mapped
to the human genome (hg18), of which 10.1% were repeats or
mapped to multiple genomic locations. The remaining 84.9% of
the tags uniquely mapped to the human genome with 9.6% of
these tags mapping to unannotated regions.
The majority of MPSS tags (75.3%) mapped to previously
characterized genes (with at least one EST sequence as evidence).
MPSS tags are categorized into different classes based on their
mapped location and orientation to known cDNAs (Refseq or
ESTs)[10,12]. We limited ourselves to the analysis of MPSS tags
that belong to classes1 through 5 as these are considered to have
more reliable annotation[10,12]. We identified a total of 13,606
class 1–5 MPSS tags of which 12,208 corresponded to 8,518
defined genes (i.e. with Entrez Gene ID or Unigene IDs). This
represented an average of 1.43 MPSS tags per gene (Table S2),
suggesting alternative polyadenylation of some genes as MPSS
technology (described in detail in the method section) captures the
last GATC tag closest to the poly A tail of genes [11]. In addition,
1,395 tags corresponded to unannotated genes or ESTs which
may represent novel transcripts or novel isoforms of known genes.
The MPSS data have been submitted to the GEO database with
the accession number GPL8198.
We found that MPSS was able to detect many transcript
expressed at low levels. Figure 1 shows the distribution of MPSS
tags at different abundance levels in transcripts per million (tpm).
We observed that about 68% of transcripts were expressed at less
than 20 tpm in normal brain tissues or GBM tissues. This
illustrates the sensitivity of next generation sequencing technology
in identifying lowly expressed transcripts.
To identify differentially expressed genes, we used the Z-test
[14,15] to compare gene expression between normal and GBM
tumor tissue. For multiple testing corrections, we computed the
false discovery rate (FDR) for each tag using statistical hypothesis
testing involving Storey’s method [15] (see Materials and Methods
for detail). Using a FDR cutoff of 0.1, we identified 3,352 tags that
show significantly differential expression (Table S3). Among these,
1,614 tags (1,391 genes) are up regulated in GBM compared to
normal brain (Table S3) and 1,738 tags (1,451 genes) are down
regulated in GBM compared to normal brain (Table S4).
Confirmation of MPSS data by real-time RT PCR and
identification of putative biomarkers for GBM
To confirm differential gene expression in individual samples,
we randomly picked two up-regulated genes, FOXM1 (forkhead
box M1) and CHI3L1 (chitinase 3-like 1), and two down regulated
genes, NRGN (neurogranin) and L1CAM (L1 cell adhesion
molecule), and evaluated them in a panel of 19 individual brain
tumor samples and 9 individual normal brain tissues. The
expression values of these genes in the MPSS data from pooled
samples are shown in Table S5. Using real time quantitative PCR,
we confirmed that CHI3L1 and FOXM1 were significantly up
regulated (P,0.05, T test) and confirmed that NRGN and
L1CAM were significantly down regulated (P,0.05, T test) in
GBM compared to normal brain tissues (Figure 2).
CHI3L1 (chitinase 3-like 1, also named YKL-40) was identified
previously as a differentially expressed gene in GBM compared
with normal brain tissues [16]. CHI3L1 is a member of
mammalian chitinase-like proteins [17]. Interestingly, there is
another member of the mammalian chitinase-like proteins,
CHI3L2 (YKL39) [18]. We were intrigued as to whether CHI3L2
is also differentially expressed. We found the CHI3L2 was also
over expressed in GBM tissues compared to normal brain tissues
(Table S5) and confirmed it by real time quantitative PCR
(Figure 2).
Identification of enriched gene sets of differentially
expressed genes in GBM compared to normal brain
tissues
To understand which Gene Ontology terms are enriched with
GBM related genes, we performed gominer (http://discover.nci.
nih.gov/gominer/) analysis. We found that genes over-expressed
in normal brain tissues compared to GBM are enriched for GO
terms related to normal brain cellular functions such as
GO:0007268 synaptic transmission, GO:0019226 transmission of
nerve impulse, GO:0007268 synaptic transmission, GO:0007399
nervous system development, GO:0048699 generation of neurons,
and GO:0050877 neurological system process.
However, GO analysis of genes over-expressed in GBM
compared to normal brain tissues revealed enrichment of general
GO terms in basic cellular metabolic and biosynthesis processes
such GO:0031328 positive regulation of cellular biosynthetic
process, GO:0045941 positive regulation of transcription,
GO:0010467 gene expression.
As this initial analysis only identified general changes related to
normal brain functions in normal tissues or increased cell
metabolism in GBM, we decided to further refine the gene sets
enriched in the differentially expressed genes between GBM and
normal brain tissues using Gene Set Enrichment Analysis (GSEA)
[19]. After GSEA, we found that there were 92 gene sets (Table
Figure 1. Bar chart showing the frequencies of MPSS tags
expressed at different levels (bins at 1–10 tpm, 11–20 tpm
etc.). Y-axis, numbers of MPSS tags; X-axis, bins of expression levels.
About half of the transcripts were expressed at low levels (,10 tpm).
doi:10.1371/journal.pone.0010210.g001
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significantly enriched in normal brain tissues. For this analysis, we
used a threshold FDR q value ,0.25 which is the standard FDR
rate recommended for GSEA analysis [19]. The top enriched gene
sets with FDR q value ,0.05 is shown in Table 1.
Of note, the top enriched gene sets include two TGF2b related
gene sets: the TGFBETA ALL UP and the TGFBETA EARLY
UP, ranked number 3 and 9 with FDR q values of 0.001 and 0.004
respectively (Table 1). The TGFBETA EARLY UP gene set
contains 58 genes found to be up-regulated by TGF-beta
treatment of skin fibroblasts at a 30 minute time point while the
TGFBETA_ALL_UP gene set contains 90 genes up-regulated by
TGF-beta treatment of skin fibroblasts at multiple early and late
time points (30, 60, 120, 240 minutes) [20]. Although the
canonical TGF2b signaling pathway gene set (defined by KEGG
pathway classification) as a whole was not significantly enriched by
GSEA analysis (FDR q value of 0.97), a visual inspection of the
overlaid gene expression changes onto the canonical TGF2b
signaling pathway revealed several genes including SMAD2 (FDR
=0.038) and SMAD7 (FDR =0.007) which were over expressed
in GBM tissues compared to normal brain tissues (Figure S1).
Activated SMAD2 is a key transducer of TGF2b signaling that
binds to SMAD4 and is translocated into the nucleus to initiate
transcription of downstream target genes. Furthermore, in
addition to TGF2b signaling itself, other members of the TGF2b
superfamily such as bone morphogenesis protein 1 (BMP1) and
genes activated through TGF2b superfamily members activin and
nodal, such as activinRIII and nodalRII, are also upregulated in
GBM (Figure S1). These pathways all act through SMAD proteins
and are considered SMAD-mediated TGF2b signaling pathways.
The TGF–b network in GBM
Pathway databases such as KEGG and other commercial and
non-commercial sources (e.g. Biocarta) typically only include a few
genes such as those listed in the canonical TGF–b signaling
pathway. GSEA, on the other hand, only provides a list of genes
without network relationships. To overcome the limited gene
number in canonical pathway maps and the lack of network links
in the enriched GSEA gene sets, we constructed a TGF–b network
which could then be overlaid with our gene expression data. The
overlaid network was displayed in the network browser Cytoscape
which allowed identification of key nodal changes in the network.
As previously described, we chose TGF–b to demonstrate the
utility of this approach as we had identified two TGF–b related
gene sets as the top ranking gene sets (Table 1) and observed
several significant gene expression changes in the canonical TGF–
b pathway. For analysis, we first constructed a TGF–b interaction
network by compiling all existing public information with no new
edges added from our data. The resulting network was then
overlaid with expression ratios (red colored nodes indicate over-
expression and blue colored nodes indicate under-expression) from
our MPSS analysis of GBM tissues and normal brain tissues. This
allowed for the identification of key changes in the network when
comparing normal brain tissue and GBM.
Figure 2. Bar charts showing the quantitative RT-PCR results of
CHI3L1, CHI3L2, FOXM1, NRGN and L1CAM on a panel of 19
individual brain tumor samples (SN series) and 9 individual
normal brain tissue samples (NGRL series). Black bars, NGRL series
(normal) samples; white, SN series (GBM) samples. Y-axis indicates
relative expression levels and X-axis indicates individual samples. Three
replicate PCR were performed and the standard errors of the mean
were indicated by error bars.
doi:10.1371/journal.pone.0010210.g002
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NAME SIZE ES NES NOM p-val FDR q-val
Enriched gene sets in GBM
STEMCELL_NEURAL_UP 370 20.2 23.6 0.0000 0.0000
CARIES_PULP_UP 40 20.4 23.3 0.0000 0.0000
TGFBETA_ALL_UP 30 20.4 22.9 0.0000 0.0014
HSA04115_P53_SIGNALING_PATHWAY 16 20.6 22.8 0.0000 0.0014
CMV_24HRS_DN 23 20.5 22.7 0.0000 0.0028
LEI_MYB_REGULATED_GENES 81 20.3 22.6 0.0000 0.0028
BREAST_CANCER_ESTROGEN_SIGNALING 24 20.4 22.5 0.0000 0.0035
CMV_ALL_DN 31 20.4 22.5 0.0000 0.0031
TGFBETA_EARLY_UP 21 20.5 22.5 0.0000 0.0035
CELL_CYCLE_KEGG 18 20.5 22.5 0.0000 0.0060
VHL_NORMAL_UP 115 20.2 22.4 0.0000 0.0067
G1_TO_S_CELL_CYCLE_REACTOME 15 20.5 22.4 0.0000 0.0087
CELL_CYCLE 17 20.5 22.4 0.0000 0.0085
GAY_YY1_DN 53 20.3 22.3 0.0000 0.0116
HSA05222_SMALL_CELL_LUNG_CANCER 16 20.5 22.3 0.0020 0.0148
CARIES_PULP_HIGH_UP 16 20.5 22.3 0.0020 0.0231
ALZHEIMERS_DISEASE_UP 300 20.1 22.2 0.0000 0.0228
HUMAN_CD34_ENRICHED_TRANSCRIPTION_FACTORS 37 20.3 22.2 0.0000 0.0229
LEE_MYC_E2F1_UP 15 20.5 22.2 0.0000 0.0240
LEE_E2F1_UP 16 20.5 22.2 0.0040 0.0250
KENNY_WNT_UP 15 20.5 22.2 0.0000 0.0272
STEMCELL_EMBRYONIC_UP 210 20.1 22.2 0.0000 0.0308
CANCER_NEOPLASTIC_META_UP 25 20.4 22.1 0.0000 0.0319
IDX_TSA_UP_CLUSTER3 18 20.4 22.1 0.0042 0.0399
SERUM_FIBROBLAST_CELLCYCLE 22 20.4 22.1 0.0038 0.0424
TNFALPHA_ALL_UP 21 20.4 22.1 0.0000 0.0455
LEE_TCELLS10_UP 19 20.4 22.1 0.0019 0.0463
ESR_FIBROBLAST_UP 18 20.4 22.0 0.0022 0.0488
LEE_TCELLS8_UP 19 20.4 22.0 0.0000 0.0477
LEE_TCELLS1_UP 19 20.4 22.0 0.0060 0.0482
AGEING_KIDNEY_SPECIFIC_UP 36 20.3 22.0 0.0040 0.0487
UVB_NHEK1_DN 43 20.3 22.0 0.0040 0.0489
LEE_TCELLS2_UP 202 20.1 22.0 0.0020 0.0477
SHEPARD_BMYB_MORPHOLINO_DN 38 20.3 22.0 0.0082 0.0469
HSA03010_RIBOSOME 34 20.3 22.0 0.0021 0.0458
WIELAND_HEPATITIS_B_INDUCED 22 20.4 22.0 0.0000 0.0448
RAS_ONCOGENIC_SIGNATURE 47 20.3 22.0 0.0039 0.0468
HSA04512_ECM_RECEPTOR_INTERACTION 18 20.4 22.0 0.0000 0.0476
VERHAAK_AML_NPM1_MUT_VS_WT_UP 34 20.3 22.0 0.0141 0.0485
BRCA_ER_NEG 169 20.1 22.0 0.0039 0.0473
JISON_SICKLECELL_DIFF 108 20.2 22.0 0.0021 0.0482
DNA_DAMAGE_SIGNALING 19 20.4 22.0 0.0062 0.0490
Enriched gene sets in normal brain tissues
ALZHEIMERS_DISEASE_DN 342 0.3 5.8 0.0000 0.0000
CALCIUM_REGULATION_IN_CARDIAC_CELLS 39 0.4 2.9 0.0000 0.0000
ASTON_DEPRESSION_DN 54 0.3 2.4 0.0000 0.0234
DFOSB_BRAIN_8WKS_UP 17 0.5 2.4 0.0000 0.0187
AGEING_BRAIN_DN 43 0.3 2.2 0.0042 0.0467
doi:10.1371/journal.pone.0010210.t001
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genes by integrating three kinds of data type: protein-protein
interactions, microarrays and ChIP-Chip analysis. We first
identified 64 proteins that interact with TGF–b using the
Michigan Molecular Interaction tool MiMI (http://portal.ncibi.
org/gateway/mimi.html). We then compiled a list of genes
regulated by TGF–b from various microarray studies. Lesne et
al. used a brain cDNA microarray to identify TGF–b regulated
genes in TGF–b 1 treated cultures of cortical neurons and
astrocytes in the mouse [21]. We retrieved the human homologues
for these differentially expressed genes. We also included
differentially expressed genes identified by microarray studies for
TGF–b responsive genes in the GEO microarray database, which
includes TGF–b regulated genes in acute myelogenous leukemia
cells (GSE1805 in the GEO database)[22], in lung carcinoma
(A549) (GSE7436 in the GEO database), in immortalized lung
epithelial (HPL1D) cells [23], in MDA-MB-468 Smad4 positive/
negative clones treated with TGF–b (GSE2567), in human HP75
pituitary cell line [24], in breast cancer cells (GSE5265) [25] and in
two glioma cell lines U373MG and U87MG [26]. Of interest,
Scharer et al. recently used ChIP-chip technology to identify 23
direct targets of SOX4 in prostate cancer cells [27]. We added
these 23 directly targeted transcription factors to the SOX4
subnetwork [27]. In the end, we identified a list of 1,678 genes
which are either regulated by TGF–b or exhibit potential as
protein-protein interaction partners (Table S8).
As the TGF–b regulated genes that we compiled from the
microarray data above does not contain interaction information,
we used Cytoscape with the MiMI plugin [28] to identify protein-
protein interactions. Cytoscape is a widely used open source
software tool for displaying interaction of molecules [29]. The
MiMi plugin for Cytoscape (http://mimiplugin.ncibi.org/) was
developed to facilitate access to the molecular interaction data
assembled in MiMI that contains integrated data from multiple
well-known protein interaction databases using an intelligent deep-
merging approach [30]. The MiMi plugin retrieves molecular
interactions and interaction attributes from MiMI and displays the
interaction networks and attributes using Cytoscape [28]. Using
this newly defined TGF–b interaction network, we asked the
question how many genes in this network correspond to
differentially expressed genes (FDR ,0.1) that we had identified
between normal brain tissue and GBM tumors. Using this
approach, we identified a final list of 420 presumed TGF–b
regulated genes that are differentially expressed in GBM (Table
S8).
Exploring the resulting network displayed by Cytoscape
revealed a subnetwork centered around TGF–b This subnetwork
captured the canonical TGF–b signaling molecules (Figure 3). Of
note, additional interesting genes appeared in the network, of
which two interested us most: SOX4 (sex determining region Y-
box 4) and TGFBI (transforming growth factor beta 1 induced
transcript) (Figure 3). As SOX4 and TGFBI are two key genes in
the network and neither of these genes had been previously
described in GBM, we decided to further analyze the expression of
SOX4 and TGFBI in GBM.
SOX4 and TGFBI are TGF–b regulated genes over
expressed in GBM
There are three MPSS tags for SOX4 and two MPSS tags for
TGFBI sequenced in our MPSS data (Table S5). The three tags
for SOX4, although belonging to different classes, showed
significantly higher expression in GBM comparing with normal
brain tissues. However for TGFBI, there was only one tag
belonging to MPSS tag class 1 which showed marginal over-
expression in GBM compared to normal tissues (17 tpm vs 0 tpm,
FDR 0.23). To evaluate the true expression pattern of TGFBI and
Figure 3. The SMAD2 mediated module (canonical TGF beta pathway), SOX4 module and TGFBI (GENE ID:7045) module of the
TGF2b network. The expression ratios of GBM tissues to normal brain tissues are overlaid onto the network. Red color indicates over expression,
yellow color indicates no changes, and blue color indicates under expression.
doi:10.1371/journal.pone.0010210.g003
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quantitative RT-PCR on a panel of 19 individual brain tumor
samples and 9 individual normal brain tissues and showed that
TGFBI and SOX4 RNA expression are significantly higher (P
values of 3.18E-03 and 2.01E-03 respectively, T-test, two-tailed
distribution, unequal variance) in GBM tissues compared to
normal brain tissues (Figure 4). For TGFBI, there were two
clusters, one with higher TGFBI expression and another with
TGFBI levels similar to that of normal tissues. For SOX4, the
majority of the GBM tissues expressed higher levels compared to
normal tissues, with three exhibiting extremely high expression (41
to 108 times higher than the median of the expression in all tissues,
data not shown).
To further analyze whether the protein products of these two
genes are over expressed in GBM, we performed immunohisto-
chemistry analysis of SOX4 and TGFBI in 60 GBM tissues and
three normal brain tissues (TMA CS17-01-004 from Cyberdi Inc.).
For TGFBI, we observed strong tumor specific immunoreactivities
in most GBM samples with extra cellular staining pattern mainly
in tumor cells and in malignant vasculature endothelial cells but
negative staining in normal brain tissues (Figure 5). For SOX4, we
observed positive immunoreactivities in GBM samples with
nucleus staining pattern in tumor cells but negative staining in
normal brain tissues (Figure 5). Examples of IHC staining results
are shown in Figure 5 and a summary table is shown in Table 2.
Statistical analysis using Fisher’s exact test indicates that TGFBI
(GENE ID:7045) show statistically significant protein expression
differences between GBM and normal tissues (P=.0037).
However, the difference in protein expression between GBM
and normal tissues for SOX4, although at 60% positive rate in
GBM vs. 0% positive rate for normal tissues, was not statistically
significant by the Fisher’s exact test (P=0.083) (Table 2).
To determine whether TGF beta 1 indeed acts on GBM cells to
change the expression of SOX4 and TGFBI (GENE ID:7045) and
to see whether the change was acted through TGF–b receptor I
kinase (TbRI), we stimulated two different GBM cell lines,
U87MG and M059J, with TGF2b and then inhibited the
TGF2b pathway with a specific inhibitor of the TGF–b receptor
I kinase (TbRI). We detected increased expression of both TGFBI
(GENE ID:7045) and SOX4 after addition of 100 pM of TGF2b
Figure 4. Bar charts showing the quantitative RT-PCR results of SOX4 and TGFBI (GENE ID:7045) on a panel of 19 individual brain
tumor samples (SN series) and 9 individual normal brain tissue samples (NGRL series). Black bars, NGRL series (normal) samples; white, SN
series (GBM) samples. Y-axis indicates relative expression levels and X-axis indicates individual samples. Three replicate PCR were performed and the
standard errors of the mean were indicated by error bars. Both TGFBI (GENE ID:7045) and SOX4 were differentially expressed with increased
expression in GBM tissues compared to normal brain (P,0.01 for both TGFBI (GENE ID:7045) and SOX4, T-test, two-tailed distribution, unequal
variance). Please note that the Y-axis for SOX4 is in log scale in order to show the full extend of SOX4 expression in the samples.
doi:10.1371/journal.pone.0010210.g004
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also observed that M059J cells were more sensitive to TGF2b
treatment than U87 cells, responding with a higher amplitude
than in U87 cells. We also noticed that the response to TGF2b
was higher at the 24-hour than at the 3-hour time point for
TGFBI (GENE ID:7045) for both M059J and U87 cells. For
SOX4, responses were higher at the 24-hour than the 3-hour time
point in M059J cells and reversed, higher at the 3-hour than the
24-hour time point, in U87 cells (Figure 6). This suggests that
individual GBM cell lines respond differently in amplitude and in
time to TGF2b treatment. Adding the specific TbRI inhibitor
LY2109761 (Calbiochem) reversed the effects of TGF2b
stimulation resulting in decreased expression of TGFBI (GENE
ID:7045) and SOX4 (Figure 6). These data indicate that SOX4
and TGFBI (GENE ID:7045) are TGF –b responsive genes.
Discussion
We applied MPSS technology to compare the expression
profiling of a pool of five normal brain tissues to a pool of five
GBM tissues. The pooled sample strategy was used because of the
cost of doing MPSS at the time. The pooled strategy for MPSS
analysis had been validated previously in other studies. For
example, Grigoriadis et al. used a pool sample strategy for MPSS
analysis in which they identified 6,553 differentially expressed
genes between the pool of normal luminal cells and that of primary
tumors substantially enriched for epithelial cells [31]. Our dataset
should prove to be a useful resource for the research community,
however there are several limitations in our approach which
should be acknowledged. By pooling samples, biological variance
(e.g. tumor heterogeneity or true normal individual variance)
could not be measured. Although we have confirmed differential
expression of several genes by RT-PCR (Figure 2 and Table S5),
we cannot exclude the possibility that our MPSS data might over
or under estimate differential expression for other genes showing
biological variance. Furthermore, although we included technical
replicates in the MPSS analysis (replicate two stepper and replicate
3 stepper sequencing runs), variation for the sample preparation
step was not measured. Finally, there may be confounding effects
related to a small sample size in a relatively heterogeneous disease.
Our five GBM samples came from patients with primary GBM
with typical clinical characteristics (mean age =62, length of
survival ,15 months) suggesting a non-proneural classification
[32]. The non-tumor brain samples consisted of histologically-
normal temporal lobe white matter obtained from patients
undergoing surgery for epilepsy. While matched for sex (M:F
ratio 3:2), the average age of the epilepsy patients was younger
(mean age =25 years). As demonstrated in our analysis,
differential gene expression based on this MPSS strategy should
be confirmed by RT-PCR in a larger independent sample set.
In this study, we identified and confirmed that FOXM1 is over
expressed in GBM comparing to normal brain tissues. Our data is
consistent with previous observation that FOXM1 is over
expressed in GBM and its protein expression levels are inversely
correlated with patient survival [33]. Over expression and knock-
down studies of FOXM1 suggested that FOXM1 confers GBM
tumorigenicity [33] and increases tumor invasion by enhancing
matrix metalloproteinase-2 expression [34]. We confirmed that
both members of the mammalian chitinase-like proteins were over
expressed in GBM comparing to normal brain tissues (Figure 2).
YKL39 differs from YKL40: while YKL40 has chitinase activity,
YKL-39 was predicted to lack chitinase activity as it the active site
glutamate [18]. Furthermore, In contrast to YKL-40, YKL-39 is
not a glycoprotein and does not bind to heparin [18]. Western blot
and ELISA analysis suggested that YKL-40 serum levels were
significantly increased in many GBM patients and that serum
YKL-40 levels correlate with tumor grade [16]. It will be
interesting to see whether YKL-39 can be used as serum
biomarker for GBM to increase specificity and sensitivity of
cancer diagnosis and stratifications.
We identified decreased expression of NRGN (neurogranin) and
L1CAM (L1 cell adhesion molecule) in GBM tissues compared to
normal brain tissues (Figure 2). Neurogranin, a calmodulin (CaM)-
Figure 5. Examples of IHC staining of GBM and normal brain
tissue samples. A: TGFBI (GENE ID:7045) antibody staining of GBM
tissue; B: IgG staining of GBM tissue; C: TGFBI (GENE ID:7045) antibody
staining of normal brain tissue; D: IgG staining of normal brain tissue. E:
SOX4 antibody staining of GBM tissue; F: IgG staining of GBM tissue; G:
SOX4 antibody staining of normal brain tissue; H: IgG staining of normal
braintissue. Pleasesee Table1 for datasummaryoftheentiretissuearray.
doi:10.1371/journal.pone.0010210.g005
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specific gene [35]. It regulates the availability of Ca(2+)/CaM
complex and modulates the homeostasis of intracellular calcium in
neurons and it may be involved in selective vulnerability of
neurons to oxidative insults in the CNS [36]. L1CAM is a cell
adhesion molecule that plays an important role in nervous system
development, including neuronal migration and differentiation
[37]. L1CAM has been shown to be involved in C6 rat glioma cell
migration via its imunoglobulin C2-like domain [38], however, the
expression of L1CAM is lower in glioma when compared to a
neuroblastoma cell line [38]. While not surprising to find
decreased neuronal genes in GBM, the role of decreased
expression of NRGN and L1CAM may have important functional
consequences which have not been previously studied in GBM.
Visual inspection of the canonical TGF–b pathway overlaid
with MPSS derived gene expression changes revealed several
genes in the canonical TGF–b pathway up-regulated in GBM
compared to normal tissues including TGF–b 1, and its effectors
SMAD2 and SMAD7. TGF–b ligands bind to heterotetrameric
complexes of type I and type II receptors of TGF–b (TGF–bRII
and TGF–bRI), activate TGF–bRI to phosphorylate SMAD2
and/or SMAD3. Phophorylated SMAD2/3 then disassociate from
SARA (SMAD anchor for receptor activation), allowing SMAD2/
3 to bind to SMAD4. The resulting complex is then translocated
to the nucleus and activates gene transcription [39,40]. Our data
suggest that the SMAD mediated TGF–b pathway is activated in
GBM. Previously, it was shown that TGF–b expression was
increased in GBM compared to normal brain tissues and its
expression may be related to malignancy of glioma [41,42]. That
observation is consistent with our data. The role of TGF-b in
GBM is complex and not fully elucidated. TGF–b has been shown
to be involved in multiple processes in GBM including excessive
proliferation, infiltrative growth, angiogenesis and suppression of
anti-tumor immune surveillance [43]. A central question remains
as to how advanced brain tumors such as GBM lose the growth
suppressive effects of TGF–b but retain TGF–b mediated
proliferative and invasive properties [44].
We furthered the analysis of the TGF–b signaling network in
GBM by integrated analysis of TGF–b regulated genes and
differentially expressed genes between GBM and normal brain
tissues. We built an expanded TGF–b signaling network and
overlaid to it the expression changes found in GBM compared to
normal brain tissues. In additional to the canonical SMAD
mediated TGF–b signaling module, we identified two interesting
modules centered on SOX4 and TGFBI (GENE ID:7045). We
further showed that SOX4 and TGFBI (GENE ID:7045) are over
expressed at both the mRNA and protein levels in GBM
compared to normal brain tissues by quantitative RT-PCR and
IHC staining (Figure 4-5). Finally, we demonstrated that both
SOX4 and TGFBI (GENE ID:7045) are responsive to TGF–b
stimulation acting through TbRI as adding TbRI inhibitor
LY2109761 reversed the stimulative effects of TGF2b on TGFBI
(GENE ID:7045) and SOX4 expression (Figure 6).
Our integrative analysis identified that TGF2b signaling
through SOX4 or TGFBI appears to be activated in GBM
compared with normal brain tissues. In the RT-PCR data, we
noticed that SOX4 and TGFBI appear to be almost mutually
exclusive in the tumor samples, suggesting a possibility that GBM
may achieve activation of the non-canonical TGF-b through
either SOX4 or TGFBI. Further experiments would be necessary
to confirm this possibility. Recently, Ikushima et al. demonstrate
that TGF-beta induces the expression of SOX2, a stemness gene,
in glioma-initiating cells (GICs) and that the induction was
mediated by SOX4 [45]. They further showed that inhibition of
TGF-beta signaling drastically decreased the tumorigenicity of
GICs by promoting their differentiation, and that these effects
were attenuated in GICs transduced with SOX2 or SOX4. Taken
together with our findings, this study supports the potentially
important role of TGF-beta signaling through the SOX4 protein
in gliomas.
Our analysis expanded our knowledge of the TGF–b signaling
network and suggested that TGF–b signaling through SOX4
might be an alternative non-SMAD mediated TGF–b signaling
pathway. SOX4 is a transcriptional activator that may play a role
in central nerve system development [46]. SOX4 is a protein with
diverse functions and has been implicated in multiple cancers [47]
[48] [49] [50]. For example, it can regulate beta-catenin/T-cell
factor activity and proliferation of colon carcinoma cells [47]. De
Bont showed that SOX4 is over expressed by about 11 fold in
medulloblastoma compared with ependymoma and normal
cerebellum [48]. Pramoonjago et al. showed that SOX4 is one
of the most up regulated genes in adenoid cystic carcinoma (ACC)
compared to non-neoplastic tissues. They further demonstrated
that RNA interference (RNAi)-mediated RNA silencing of SOX4
increases cell apoptosis and reduces cell survival in the ACC-
derived cell line ACC3, suggesting that Sox4 could contribute to
the malignant phenotype of ACC cells by promoting cell survival
[49]. Recently, SOX4 was shown to bind to the promoter of
EGFR and transcriptionally activates EGFR [27]. Other growth
factors targeted by SOX4 include FGFRL1, and IGF2R.
Recently, both SOX4 and tenascin C were shown to enhance
metastasis of breast cancer cells to the lung [50].
We identified a TGFBI (GENE ID:7045) module containing
extracellular matrix proteins that are over expressed in GBM
compared to normal brain tissues. These genes include collagens
(e.g. COL1A2, COL1A1, COL2A1, COL4A2), MMP2 (matrix
metalloproteinase 2), SPARC (secreted protein, acidic and rich in
cysteine) and fibronectin (FN) (Figure 3). SPARC has been shown
to promote GBM invasion in intro [51] and MMP2 expression was
increased in GBMs [52]. TGFBI (GENE ID:7045) itself is an
Table 2. Summaries of IHC staining of TGFBI and SOX4 on GBM and normal brain tissues.
Pathology TGFB1 SOX4
Negative Positive Positive Rate (%) Negative Positive Positive Rate (%)
Normal 3 0 0 3 0 0
Glioblastoma 3 27 90 12 18 60
Fisher’s Exact Test .0037* .083
*P,0.05
doi:10.1371/journal.pone.0010210.t002
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cancer by enhancing cell extravasation [53].
We compared our MPSS data with the Cancer Genome Atlas
(TCGA) data for GBM (http://cancergenome.nih.gov/dataportal/)
[54]. We believe that our dataset will be a useful resource to
complement the TCGA expression data, which has been generated
using two major array platforms—Affymetrix and Agilent. For
many lowly expressed genes, the MPSS technology seems to have
better sensitivity and reliability in detecting changes in expression.
For example, evaluating the Broad-MIT’s U133A dataset (TCGA)
of 173 GBM samples for genes that we identified as up regulated by
MPSS, about 30% are expressed in the lower 20% percentile of the
array raw intensity (data not shown) and these are known not to be
reliably detected as their expression levels are close to background.
In addition, MPSS offer the advantage of identifying and comparing
different RNA isoforms for the same gene. Although we did not
discuss in detail the RNA isoforms in our dataset, our raw data
(Table S1) will be a useful resource for investigators interested in
RNA isoforms, especially the differentially polyadenylated RNA
isoforms that MPSS has a strength in identifying.
Figure 6. RT-PCR results showing the expression changes of TGFBI (GENE ID:7045) and SOX4 in response to TGF2b stimulation
with and without inhibition of TGF2b receptor I (TbRI) kinase in two GBM cell lines, M059J and U87MG. Y-axis indicates relative
expression levels with standard deviation indicated on top of the each bar. X-axis indicates cell types and treatment conditions (vehicle control,
vehicle control plus TbRI kinase inhibitor LY210976, TGF2b stimulation, TGF2b stimulation in the presence of TbRI kinase inhibitor LY210976). The
expression levels of TGFBI (GENE ID:7045) and SOX4 were measured at two time points 3 hours and 24 hours (* indicates P,0.05, T test, two-tailed
distribution, unequal variance).
doi:10.1371/journal.pone.0010210.g006
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signaling pathways acting through SOX4 and TGFBI (GENE
ID:7045) in GBM. These pathways warrant further investigation
and should be considered, in addition to the canonical SMAD
mediated pathway, in the development of new therapeutic
strategies targeting TGF2b signaling in GBM.
Materials and Methods
Ethics Statement
All patients signed a written informed consent and the data and
samples were analyzed anonymously. The present study was
approved by the Institutional Review Boards of the University of
Iowa and Swedish Medical Center.
Tissue samples and cell lines
Histologically-confirmed GBM and histologically normal non-
tumor brain specimens (temporal lobe white matter from epilepsy
resections) were obtained from the University of Iowa Hospital. All
patients gave informed consent prior to collection of specimens
according to institutional guidelines. An equal amount of RNA
from five histologically-normal non-tumor white matter specimens
were pooled and used for MPSS analysis. The same was done for
five histologically-confirmed GBM samples. The samples were
sequenced as normal pool and cancer pool (not barcoded or
multiplexed).
Glioblastoma cell line U87MG and M059J were obtained from
ATCC (http://www.atcc.org/). Both cell lines were passaged in
the laboratory for fewer than 6 months after resuscitation. The
cells were authenticated by cytogenetic analysis and typing of
isozymes by ATCC. Cells were maintained at 37uC in a 5% CO2-
95% air atmosphere in a media consisting of DMEM, 10% fetal
bovine serum, and 100 units/100 mg per ml penicillin/strepto-
mycin.
Total RNA was extracted using Trizol (Invitrogen, Carlsbad,
CA) and additional purification performed using RNeasy MinE-
lute Cleanup kit (Qiagen, Valencia, CA) before quality assessment
with the Agilent Bioanalyzer (Palo Alto, CA).
MPSS analysis
A pool of five normal brain tissues and a pool of five GBM
tissues were analyzed by the ‘‘signature cloning’’ variety of the
MPSS technology. In brief, RNAs were captured with microbeads
containing olido dT and cDNA synthesized on beads. cDNA were
then digested by DpnII restriction enzyme and the Dpn-II-to-
polyA-fragments were captured on beads. An adaptor with MmeI
recognition site was ligated to the 59-ends of the Dpn-II-to-polyA-
fragments, followed by MmeI digestion that cuts 21–22 bases
downstream. This 21–22 base signature from each transcript was
subsequently cloned using adaptors and loaded to microbeads for
sequencing. The libraries were constructed and sequenced at Lynx
Therapeutics, Inc (now Illumina Inc.) (Hayward, CA). For
sequencing the MPSS tags, sequencing runs were done by using
two different sequencing reactions that results in sequence
determination that is offset by two bases (2-step) or three bases
(3-step) as described previously [11]. }. These sequencing reactions
are hereafter called steppers i.e. ‘‘2-stepper’’ or ‘‘3-stepper’’. Four
technical replicates were conducted for individual sequencing
runs. After 2-stepper or three-stepper sequencing determination,
the counts for a given tag were summed and averaged by the two-
stepper or the three-stepper sequencing reactions. The sequencing
stepper with higher count average was selected to represent the
tag. Replicated runs of the chosen stepper sequencing were
averaged as the final representation for the tag. The expression
data were normalized to per million, which is expressed as tags per
million (tpm).
Identification of differentially expressed genes (DEGs)
The following method was applied to compute the FDR using
two sets of two technical replicates: for the normal or GBM
sample, two sets of tag counts from two independent sequencing
runs of the same sample. First, to compute a distribution of the
complete null hypothesis that the tag counts were not different
between normal and GBM, we applied the Z-test in powerSAGE
[15] to 1) two normal and 2) two GBM technical replicates (i.e.
normal vs. normal and GBM vs. GBM), resulting in two sets of
p-values from the two comparisons. Second, we then computed Z
values for the two sets of p-values as 1-Ncdf
21(P) where Ncdf
21 is
the inverse function of the standard normal cumulative density
function, and P is a p-value for each tag from the Z-test. Third,
we combined the Z values for the two sets of p-values to generate
an empirical distribution of the null hypothesis. Fourth, we
computed the Z values for the normal vs. GBM comparison by
applying the Z-test to the mean tag counts of normal and GBM
technical replicates and then applying 1-Ncdf
21(P) to the
resulting p-values from the Z-test. Fifth, for a Z value (Zi)f o r
each tag (ti) from the previous step, the expected fraction of false
positives under the complete null hypothesis was estimated as the
fraction of tags with Z . Zi in the empirical null hypothesis
distribution. Sixth, for each tag, FDR was computed as the
expected fraction of false positives multiplied by two times the
number of tags with p-values.0.5 divided by the total number of
tags, according to Storey’s method [55,56]. Finally, the
differentially expressed genes were selected as the tags with
FDR,0.1. To identify differential expression for genes with
multiple tags, where different tags could represent different
isoforms of the same gene, we accounted for and analyzed each of
the individual tags. As long as one of the tags of a gene showed
differentially expression, we considered the gene as differentially
expressed.
Gene ontology and pathway enrichment analysis
For gene ontology analysis, we used gominer (http://discover.
nci.nih.gov/gominer/). The background list was all transcripts
identified by MPSS. GO biological processes at level 3 were used
for gene ontology categories. GO terms with FDR ,0.05 were
considered significantly enriched. For GSEA analysis (http://
www.broad.mit.edu/gsea/index.jsp), we used the molecular sig-
nature database C2, which contains 1892 curated gene sets that
are collected from various sources including online pathway
databases and knowledge of domain experts. Permutations of the
gene sets 1000 times were performed to calculate the P values and
FDR q values. Other basic parameters were set as default except
the metric for ranking genes was set to ratio of classes; minimum
size of enriched sets, 15.
Real-time quantitative PCR
Purified RNA (1 mg) was reverse transcribed using random
primers (Applied Biosystems). The resulting cDNA is diluted 25
fold and used as template. Real-time PCR is performed using
Assay on Demand gene expression reagents (Applied Biosystems)
on ABI PRISM 7900 HT Sequence Detection System under
default conditions: 95uC for 10 min, and 40 cycles of 95uC for 15 s
and 60uC for 1 min. The expression of human GUS (beta
glucuronidase) was used as endogenous control and comparative
Ct method was used for quantification of the transcripts.
Measurement of DCt was performed in triplicate.
SOX4 and TGFBI in Glioblastoma
PLoS ONE | www.plosone.org 10 April 2010 | Volume 5 | Issue 4 | e10210Imunohistochemistry
Rabbit polyclonal anti-human TGFBI (GENE ID:7045)
(Transforming Growth Factor-Beta Induced, 68-KD;) antibody
(Proteintech Group, Cat# 10188-1-AP) and Rabbit polyclonal
anti-human SOX4 antibody (Abcam, Cat# 52043) were used for
IHC staining. For control, Mouse IgG isotype control antibody
250 ug/ml (BD, Cat# 550878) and Rabbit IgG isotype control
antibody 5 mg/ml (Southern Biotech, Cat# 0111-01) were used.
Brain tissue array (Lot ID: CS17-01-004) from Cybrdi, Inc.
was used (http://cybrdi.com/viewproduct.php?id=305). Tissue
arrays were formalin fixed, paraffin embedded (PPFE) array slides.
Each tissue array contained 60 paired tissue cores from 30
different GBM tumor samples and three tissue cores from normal
brain. The tissue array core diameter was 1.5 mm with a core
thickness of 5 mM.
We used the IHC services provided by Cybrdi, Inc. including
antibody optimization, IHC staining, pathological reading and
scoring by experienced pathologists. Primary antibodies for
TGFBI (GENE ID:7045) and SOX4 were diluted at 1:100, 1:25
respectively for IHC. Secondary antibody was used at 1:200
dilution. For isotype control antibodies, rabbit IgG was used at
1:25 and murine IgG was used at 1:10. The scoring criteria
contain two parameters, percentage of positive cell population and
staining intensities. For percentage of positive cell population, the
categories are: 0=0% of the cell population is positive; 1=1 to
25% of the cell population is positive: 2=26 to 50% of the cell
population is positive: 3=51 to 75% of the cell population is
positive: 4=76 to 100% of the cell population is positive. The
staining intensities were scored as: - = Negative staining; + =
Weak staining intensity; ++ = Medium staining intensity; +++ =
Strong staining intensity.
TGF2b treatments
Human Glioma cell lines (U87MG and M059J) were serum
deprived for 24 hrs prior to treatment of TGF2b 1 (Gene ID:
7040) (100 pM, R&D Systems) and/or TGF2b 1 Receptor
Kinase Inhibitor (LY-364947, 2 uM, Cal biochem) for 3 hr or
24 hrs in serum-free media.
Supporting Information
Table S1 All MPSS tags identified and their expression data in
the normal brain tissues and the GBM tissues.
Found at: doi:10.1371/journal.pone.0010210.s001 (5.78 MB
XLS)
Table S2 Known genes belonging to MPSS class 1 to 5.
Found at: doi:10.1371/journal.pone.0010210.s002 (4.27 MB
XLS)
Table S3 Up-regulated genes in GBM tissues compared with
normal tissues.
Found at: doi:10.1371/journal.pone.0010210.s003 (0.46 MB
XLS)
Table S4 Down-regulated genes in in GBM tissues compared
with normal tissues.
Found at: doi:10.1371/journal.pone.0010210.s004 (0.48 MB
XLS)
Table S5 Selected genes for PCR.
Found at: doi:10.1371/journal.pone.0010210.s005 (0.03 MB
XLS)
Table S6 Enriched gene sets in GBM tissues.
Found at: doi:10.1371/journal.pone.0010210.s006 (0.03 MB
XLS)
Table S7 Enriched gene sets in normal brain tissues.
Found at: doi:10.1371/journal.pone.0010210.s007 (0.02 MB
XLS)
Table S8 TGF beta related genes differentially expressed
between GBM and normal tissues.
Found at: doi:10.1371/journal.pone.0010210.s008 (0.09 MB
XLS)
Figure S1 The canonical TGF2b pathway in KEGG with
overlaid expression changes of GBM tissues to normal brain
tissues. Red color indicates up-regulated and blue color indicates
down regulated genes. Yellow color indicates no significant change
in expression was observed.
Found at: doi:10.1371/journal.pone.0010210.s009 (2.94 MB TIF)
Author Contributions
Conceived and designed the experiments: BL AM LH GF. Performed the
experiments: BL AM JGY XF. Analyzed the data: BL AM JGY XY TKK
DH. Contributed reagents/materials/analysis tools: TKK LH GF. Wrote
the paper: BL AM GF.
References
1. van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, et al. (2003)
Characterization of gene expression profiles associated with glioma progression
using oligonucleotide-based microarray analysis and real-time reverse transcrip-
tion-polymerase chain reaction. Am J Pathol 163: 1033–1043.
2. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, et al. (2003) Identification of
molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22:
2361–2373.
3. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, et al. (2005) Gene
expression profiling reveals molecularly and clinically distinct subtypes of
glioblastoma multiforme. Proc Natl Acad Sci U S A 102: 5814–5819.
4. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern
of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:
157–173.
5. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, et al. (2005) Gene
expression profiling and genetic markers in glioblastoma survival. Cancer Res
65: 4051–4058.
6. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, et al. (2004)
Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64:
6503–6510.
7. Foltz G, Ryu GY, Yoon JG, Nelson T, Fahey J, et al. (2006) Genome-wide
analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate
tumor suppressor genes in malignant glioma. Cancer Res 66: 6665–
6674.
8. Foltz G, Yoon JG, Lee H, Ryken TC, Sibenaller Z, et al. (2009) DNA
methyltransferase-mediated transcriptional silencing in malignant glioma: a
combined whole-genome microarray and promoter array analysis. Oncogene.
9. Wang Y, Li Y, Liu S, Shen W, Jiang B, et al. (2005) Study on the dynamic
behavior of a DNA microarray. J Nanosci Nanotechnol 5: 1249–1255.
10. Lin B, White JT, Lu W, Xie T, Utleg AG, et al. (2005) Evidence for the presence
of disease-perturbed networks in prostate cancer cells by genomic and proteomic
analyses: a systems approach to disease. Cancer Res 65: 3081–3091.
11. Brenner S, Johnson M, Bridgham J, Golda G, Lloyd DH, et al. (2000) Gene
expression analysis by massively parallel signature sequencing (MPSS) on
microbead arrays. Nat Biotechnol 18: 630–634.
12. Jongeneel CV, Delorenzi M, Iseli C, Zhou D, Haudenschild CD, et al. (2005) An
atlas of human gene expression from massively parallel signature sequencing
(MPSS). Genome Res 15: 1007–1014.
13. Oudes AJ, Roach JC, Walashek LS, Eichner LJ, True LD, et al. (2005)
Application of Affymetrix array and Massively Parallel Signature Sequencing for
identification of genes involved in prostate cancer progression. BMC Cancer 5:
86.
14. Kal AJ, van Zonneveld AJ, Benes V, van den Berg M, Koerkamp MG, et al.
(1999) Dynamics of gene expression revealed by comparison of serial analysis of
gene expression transcript profiles from yeast grown on two different carbon
sources. Mol Biol Cell 10: 1859–1872.
15. Man MZ, Wang X, Wang Y (2000) POWER_SAGE: comparing statistical tests
for SAGE experiments. Bioinformatics 16: 953–959.
SOX4 and TGFBI in Glioblastoma
PLoS ONE | www.plosone.org 11 April 2010 | Volume 5 | Issue 4 | e1021016. Tanwar MK, Gilbert MR, Holland EC (2002) Gene expression microarray
analysis reveals YKL-40 to be a potential serum marker for malignant character
in human glioma. Cancer Res 62: 4364–4368.
17. Rehli M, Krause SW, Andreesen R (1997) Molecular characterization of the
gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein
family and marker for late stages of macrophage differentiation. Genomics 43:
221–225.
18. Hu B, Trinh K, Figueira WF, Price PA (1996) Isolation and sequence of a novel
human chondrocyte protein related to mammalian members of the chitinase
protein family. J Biol Chem 271: 19415–19420.
19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005)
Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–15550.
20. Verrecchia F, Chu ML, Mauviel A (2001) Identification of novel TGF-beta/
Smad gene targets in dermal fibroblasts using a combined cDNA microarray/
promoter transactivation approach. J Biol Chem 276: 17058–17062.
21. Lesne S, Blanchet S, Docagne F, Liot G, Plawinski L, et al. (2002) Transforming
growth factor-beta1-modulated cerebral gene expression. J Cereb Blood Flow
Metab 22: 1114–1123.
22. Scandura JM, Boccuni P, Massague J, Nimer SD (2004) Transforming growth
factor beta-induced cell cycle arrest of human hematopoietic cells requires
p57KIP2 up-regulation. Proc Natl Acad Sci U S A 101: 15231–15236.
23. Ranganathan P, Agrawal A, Bhushan R, Chavalmane AK, Kalathur RK, et al.
(2007) Expression profiling of genes regulated by TGF-beta: differential
regulation in normal and tumour cells. BMC Genomics 8: 98.
24. Ruebel KH, Leontovich AA, Tanizaki Y, Jin L, Stilling GA, et al. (2008) Effects
of TGFbeta1 on gene expression in the HP75 human pituitary tumor cell line
identified by gene expression profiling. Endocrine 33: 62–76.
25. Tang B, Yoo N, Vu M, Mamura M, Nam JS, et al. (2007) Transforming growth
factor-beta can suppress tumorigenesis through effects on the putative cancer
stem or early progenitor cell and committed progeny in a breast cancer
xenograft model. Cancer Res 67: 8643–8652.
26. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, et al. (2007) High TGFbeta-
Smad activity confers poor prognosis in glioma patients and promotes cell
proliferation depending on the methylation of the PDGF-B gene. Cancer Cell
11: 147–160.
27. Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, et al. (2009)
Genome-wide promoter analysis of the SOX4 transcriptional network in
prostate cancer cells. Cancer Res 69: 709–717.
28. Gao J, Ade AS, Tarcea VG, Weymouth TE, Mirel BR, et al. (2009) Integrating
and annotating the interactome using the MiMI plugin for cytoscape.
Bioinformatics 25: 137–138.
29. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a
software environment for integrated models of biomolecular interaction
networks. Genome Res 13: 2498–2504.
30. Jayapandian M, Chapman A, Tarcea VG, Yu C, Elkiss A, et al. (2007) Michigan
Molecular Interactions (MiMI): putting the jigsaw puzzle together. Nucleic Acids
Res 35: D566–571.
31. Grigoriadis A, Mackay A, Reis-Filho JS, Steele D, Iseli C, et al. (2006)
Establishment of the epithelial-specific transcriptome of normal and malignant
human breast cells based on MPSS and array expression data. Breast Cancer
Res 8: R56.
32. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The
2007 WHO classification of tumours of the central nervous system. Acta
Neuropathol 114: 97–109.
33. Liu M, Dai B, Kang SH, Ban K, Huang FJ, et al. (2006) FoxM1B is
overexpressed in human glioblastomas and critically regulates the tumorigenicity
of glioma cells. Cancer Res 66: 3593–3602.
34. Dai B, Kang SH, Gong W, Liu M, Aldape KD, et al. (2007) Aberrant FoxM1B
expression increases matrix metalloproteinase-2 transcription and enhances the
invasion of glioma cells. Oncogene 26: 6212–6219.
35. Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J (1990)
Neurogranin: immunocytochemical localization of a brain-specific protein
kinase C substrate. J Neurosci 10: 3782–3792.
36. Gui J, Song Y, Han NL, Sheu FS (2007) Characterization of transcriptional
regulation of neurogranin by nitric oxide and the role of neurogranin in SNP-
induced cell death: implication of neurogranin in an increased neuronal
susceptibility to oxidative stress. Int J Biol Sci 3: 212–224.
37. Wolff JM, Frank R, Mujoo K, Spiro RC, Reisfeld RA, et al. (1988) A human
brain glycoprotein related to the mouse cell adhesion molecule L1. J Biol Chem
263: 11943–11947.
38. Izumoto S, Ohnishi T, Arita N, Hiraga S, Taki T, et al. (1996) Gene expression
of neural cell adhesion molecule L1 in malignant gliomas and biological
significance of L1 in glioma invasion. Cancer Res 56: 1440–1444.
39. Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta signalling from cell
membrane to nucleus through SMAD proteins. Nature 390: 465–471.
40. Massague J (1998) TGF-beta signal transduction. Annu Rev Biochem 67:
753–791.
41. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, et al. (2000)
Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at
different stages of human glioma. Int J Cancer 89: 251–258.
42. Kawataki T, Naganuma H, Sasaki A, Yoshikawa H, Tasaka K, et al. (2000)
Correlation of thrombospondin-1 and transforming growth factor-beta expres-
sion with malignancy of glioma. Neuropathology 20: 161–169.
43. Platten M, Wick W, Weller M (2001) Malignant glioma biology: role for TGF-
beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech
52: 401–410.
44. Piek E, Westermark U, Kastemar M, Heldin CH, van Zoelen EJ, et al. (1999)
Expression of transforming-growth-factor (TGF)-beta receptors and Smad
proteins in glioblastoma cell lines with distinct responses to TGF-beta1.
Int J Cancer 80: 756–763.
45. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, et al. (2009) Autocrine
TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through
Sry-related HMG-box factors. Cell Stem Cell 5: 504–514.
46. Cheung M, Abu-Elmagd M, Clevers H, Scotting PJ (2000) Roles of Sox4 in
central nervous system development. Brain Res Mol Brain Res 79: 180–191.
47. Sinner D, Kordich JJ, Spence JR, Opoka R, Rankin S, et al. (2007) Sox17 and
Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation
of colon carcinoma cells. Mol Cell Biol 27: 7802–7815.
48. de Bont JM, Kros JM, Passier MM, Reddingius RE, Sillevis Smitt PA, et al.
(2008) Differential expression and prognostic significance of SOX genes in
pediatric medulloblastoma and ependymoma identified by microarray analysis.
Neuro Oncol 10: 648–660.
49. Pramoonjago P, Baras AS, Moskaluk CA (2006) Knockdown of Sox4 expression
by RNAi induces apoptosis in ACC3 cells. Oncogene 25: 5626–5639.
50. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, et al. (2008)
Endogenous human microRNAs that suppress breast cancer metastasis. Nature
451: 147–152.
51. Golembieski WA, Ge S, Nelson K, Mikkelsen T, Rempel SA (1999) Increased
SPARC expression promotes U87 glioblastoma invasion in vitro. Int J Dev
Neurosci 17: 463–472.
52. Munaut C, Noel A, Hougrand O, Foidart JM, Boniver J, et al. (2003) Vascular
endothelial growth factor expression correlates with matrix metalloproteinases
MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 106:
848–855.
53. Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, et al. (2008) Extracellular
matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by
enhancing cell extravasation. Genes Dev 22: 308–321.
54. Network TCGAR (2008) Comprehensive genomic characterization defines
human glioblastoma genes and core pathways. Nature 455: 1061–1068.
55. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies.
Proc Natl Acad Sci U S A 100: 9440–9445.
56. Westfall PH, Young SS (1993) Resampling-Based Multiple Testing: Examples
and Methods for P-Value Adjustment. New York: Wiley.
SOX4 and TGFBI in Glioblastoma
PLoS ONE | www.plosone.org 12 April 2010 | Volume 5 | Issue 4 | e10210